On 2014 Aug 10, Matthew Katz commented:

CALGB 8433 proved the ability to improve cure rates in non-small cell lung cancer by combining chemotherapy with radiation. As of 2014, platinum-based regimens are still standard. The trend has been toward concurrent chemoradiation based on small increases in survival. But some patients still may benefit from a sequential approach to treatment.

On 2014 Aug 10, Matthew Katz commented:

CALGB 8433 proved the ability to improve cure rates in non-small cell lung cancer by combining chemotherapy with radiation. As of 2014, platinum-based regimens are still standard. The trend has been toward concurrent chemoradiation based on small increases in survival. But some patients still may benefit from a sequential approach to treatment.